| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP and GC
1 company
Glenn Baity last filed a Form 4 in April 2018, as EVP and GC at ACAD. From March 2016 to January 2018, the filings on record show 0 open-market purchases and 14 sales. Glenn Baity's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 83,734 shares of ACAD. The ACAD filings lean toward selling, a net 339,651 shares.
Shares as reported in the last Form 4 for each company; the most recent is from April 2018. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2016 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 10,000 | $30.00 | $300,001.00 | -12.3% | |
| Nov 10, 2016 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 10,200 | $30.07 | $306,687.48 | -13.9% | |
| Jul 12, 2016 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 16,000 | $35.00 | $560,032.77 | -20.3% | |
| Mar 2, 2016 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 7,000 | $20.80 | $145,579.70 | -10.0% |